1092953-04-2

Basic information

• Product Name: ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate
• Synonyms: ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate
• CAS NO: 1092953-04-2
• Molecular Weight: 503.189
• Mol File: 1092953-04-2.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate(1092953-04-2)
• EPA Substance Registry System: ethyl 4-(2-bromo-4-fluorophenyl)-6-(bromomethyl)-2-(thiazol-2-yl)-1,4-dihydro-pyrimidine-5-carboxylate(1092953-04-2)

Safety Data

• Hazardous Substances Data: 1092953-04-2(Hazardous Substances Data)

Upstream product

• 1092952-98-1 ethyl 4-(2-bromo-4-fluorophenyl)-6-methyl-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate 
• 59142-68-6 2-bromo-4-fluorobenzaldehyde 
• 141-97-9 ethyl acetoacetate 

Downstream Products

• 1092970-12-1 ethyl (R,S)-6-(2-bromo-4-fluorophenyl)-4-(morpholinomethyl)-2-(thiazol-2-yl)-1,6-dihydropyrimidine-5-carboxylate 
• 1571211-74-9 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-3-carboxylic acid 
• 1571214-96-4 isopropyl 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydro-pyrimidin-4-yl)methyl)morpholine-3-carboxylate 
• 1571217-89-4 ethyl 4-(2-bromo-4-fluorophenyl)-6-((3-(methylcarbamoyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate 
• 1571219-25-4 ethyl 4-(2-bromo-4-fluorophenyl)-6-(((S)-2-(hydroxymethyl)morpholino)methyl)-2-(thiazol-2-yl)-1,4-dihydropyrimidine-5-carboxylate 
• 1571211-95-4 4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholine-2-carboxylic acid 
• 1571212-14-0 2-(4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)acetic acid 
• 1571214-87-3 2-(4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acetic acid 
• 1571212-16-2 3-(4-((6-(2-bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-3-yl)propanoic acid 

Relevant articles and documents

Design, synthesis and evaluation of heteroaryldihydropyrimidine analogues bearing spiro ring as hepatitis B virus capsid protein inhibitors

GLS4, a potent antiviral drug candidate, has been widely studied and entered into phase II clinical trials. Nevertheless, the therapeutic application of GLS4 is limited due to poor water solubility, short half-life, and low bioavailability. In order to improve the hydrophilicity and pharmacokinetic (PK) properties of GLS4, herein, we retained the dominant fragments, and used a scaffold hopping strategy to replace the easily metabolized morpholine ring of GLS4 with diverse sizes of spiro rings consisting of hydrogen bond donor and acceptor substituents. Potent in vitro anti-HBV activity and low cytotoxicity were observed for compound 4r (EC50 = 0.20 ± 0.00 μM, CC50 > 87.03 μM), which was more potent than the positive control lamivudine (EC50 = 0.37 ± 0.04 μM, CC50 > 100.00 μM) in this assay and was about a quarter as effective as GLS4 (EC50 = 0.045 ± 0.01 μM, CC50 > 99.20 μM). Preliminary structure-activity relationship (SAR) analysis and molecular docking studies were carried out to explore potential interactions and binding mode between compounds and target protein. In terms of the physicochemical properties, 4r was predicted to be consistent with the rule-of-five, which means 4r may have favourable absorption and permeation. Finally, ADMET and PK characteristics of 4r and GLS4 were predicted to be comparable in most aspects, implying that the two compounds may have similar profiles in vivo.

Dihydropyrimidine-pomalidomide conjugate as well as preparation method and application thereof

The invention provides a dihydropyrimidine-pomalidomide conjugate as well as a preparation method and application thereof. The conjugate has a structure as shown in a formula I. The invention further relates to a preparation method of the compound with the structure as shown in the formula I, a pharmaceutical composition and application of the compound in preparation of anti-HBV drugs.

Dihydropyrimidine prodrug, preparation method and applications thereof

The invention discloses a dihydropyrimidine prodrug, a preparation method and applications thereof, wherein the compound has a structure defined in the specification. The invention further relates toa preparation method of the compound, a pharmaceutical composition, and applications of the compound in the preparation of anti-HBV drugs.